Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Aisling Capital Reduces Stake in Cempra Inc (CEMP)

Dennis Purcell‘s Aisling Capital recently filed an amended 13D with the SEC disclosing a reduced stake in Cempra Inc (NASDAQ:CEMP). According to the filing, Aisling Capital now owns 2.23 million shares which includes 39,218 shares of common stock issuable upon the exercise of preferred share purchase warrants expiring on August 5, 2018. This represents 5.1% of the outstanding common stock of Cempra. The latest filing represents a slight decrease to Aisling’s position, which held 3.29 million shares of Cempra at the end of the first quarter. Aisling’s investment in Cempra dates all the way back to 2006.


Cempra Inc (NASDAQ:CEMP) is a drug discovery and development company focused on infectious diseases and the treatment of drug-resistant bacteria. The company’s lead product is Solithromycin (CEM-101) which is for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin is active against many key CABP pathogens as well as against pneumococcal strains resistant to other macrolides. The product is in Phase III clinical trials. Cempra Inc (NASDAQ:CEMP)’s Taksta is an antibiotic used for the long term oral treatment of prosthetic joint infections (PJI), caused by staphylococci, including S. aureus and methicillin-resistant Staphylococcus aureus (MRSA). Taksta has completed its Phase II clinical trials.

Aisling Capital is an early stage investment fund with a focus on healthcare. It has about $1.6 billion in assets under management and was founded by Purcell.  Prior to Aisling, Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q for over five years. Prior to H&Q, Purcell was a Managing Director in the Healthcare Group at PaineWebber. Purcell has an MBA from Harvard University and a BS in accounting from the University of Delaware.

Disclosure: None

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!